Please wait while the formulary information is being retrieved.
HIZENTRA (IMMUNE GLOBULIN,GAMMA(IGG))
- Primary immune deficiency disorder
- Agammaglobulinemia
- Chronic inflammatory demyelinating polyneuropathy
- Common variable agammaglobulinemia
- Severe combined immunodeficiency disease
- Wiskott-aldrich syndrome
- X-linked agammaglobulinemia
1 gram/5 mL (20 %) subcutaneous solution
- Inject 200 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
10 gram/50 mL (20 %) subcutaneous solution
- Inject 200 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
2 gram/10 mL (20 %) subcutaneous solution
- Inject 200 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
4 gram/20 mL (20 %) subcutaneous solution
- Inject 200 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
Agammaglobulinemia
- Inject 50 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 300 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 333.33 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 400 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 600 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 300 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 333.33 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 50 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 400 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 600 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
Chronic inflammatory demyelinating polyneuropathy
- Inject 200 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 400 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
Common variable agammaglobulinemia
- Inject 50 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 300 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 333.33 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 400 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 600 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 300 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 333.33 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 50 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 400 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 600 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
Primary immune deficiency disorder
- Inject 50 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 300 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 333.33 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 400 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 600 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 300 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 333.33 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 50 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 400 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 600 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
Severe combined immunodeficiency disease
- Inject 50 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 300 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 333.33 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 400 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 600 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 300 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 333.33 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 50 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 400 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 600 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
Wiskott-aldrich syndrome
- Inject 50 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 300 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 333.33 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 400 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 600 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 300 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 333.33 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 50 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 400 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 600 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
X-linked agammaglobulinemia
- Inject 50 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 300 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 333.33 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 4 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 400 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 600 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 4 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 300 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 333.33 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 50 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route once weekly not to exceed 8 separate injection sites at the same time
- Inject 100 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 200 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 400 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- Inject 600 mg/kg via infusion pump by subcutaneous route every 14 days not to exceed 8 separate injection sites at the same time
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- Proquad (pf)
- varicella virus vacc live (PF)
- Varivax (pf)
- yellow fever vaccine live (PF)
- Yf-vax (pf)
Contraindicated
- None
Severe
Moderate
- Activella
- Alora
- Altavera (28)
- Alyacen 1/35 (28)
- Alyacen 7/7/7 (28)
- Amethia
- Amethia Lo
- Amethyst
- Angeliq
- Apri
- Aranelle (28)
- Aubra
- Aviane
- Azurette (28)
- Balziva (28)
- Beyaz
- Brevicon (28)
- Briellyn
- Camrese
- Camrese Lo
- Caziant (28)
- Cenestin
- Chateal
- Climara
- Climara Pro
- Combipatch
- conj estrogens-bazedoxifene
- conjugated estrogens
- Covaryx
- Covaryx H.s.
- Cryselle (28)
- Cyclafem 1/35 (28)
- Cyclafem 7/7/7 (28)
- Cyclessa (28)
- Dasetta 1/35 (28)
- Dasetta 7/7/7 (28)
- Daysee
- Delestrogen
- Depo-estradiol
- desog-e.estradiol/e.estradiol
- Desogen
- desogestrel-ethinyl estradiol
- Divigel
- drospirenone-e.estradiol-lm.FA
- drospirenone-estradiol
- drospirenone-ethinyl estradiol
- Duavee
- Eemt
- Eemt Hs
- Elestrin
- Elinest
- Emoquette
- Enjuvia
- Enpresse
- Enskyce
- Estarylla
- esterified estrogens
- Estrace
- estradiol
- estradiol acetate
- estradiol cypionate
- Estradiol Transdermal Patch
- estradiol valerate
- estradiol valerate-dienogest
- estradiol-levonorgestrel
- estradiol-norethindrone acet
- estradiol-norgestimate
- Estrasorb
- Estring
- Estrogel
- estrogens-methyltestosterone
- estropipate
- Estrostep Fe-28
- ethynodiol diac-eth estradiol
- etonogestrel-ethinyl estradiol
- Evamist
- Falmina (28)
- Femcon Fe
- Femhrt Low Dose
- Femring
- Generess Fe
- Gianvi (28)
- Gildagia
- Gildess
- Gildess Fe
- Introvale
- Jinteli
- Jolessa
- Junel 1.5/30 (21)
- Junel 1/20 (21)
- Junel Fe 1.5/30 (28)
- Junel Fe 1/20 (28)
- Kariva (28)
- Kelnor 1/35 (28)
- Kurvelo
- L norgest&E estradiol-E estrad
- Larin 1/20 (21)
- Larin Fe
- Leena 28
- Lessina
- Levonest (28)
- levonorg-eth estrad triphasic
- levonorgestrel-ethinyl estrad
- Levora 0.15/30 (28)
- Levora-28
- Lo Loestrin Fe
- Loestrin 1.5/30 (21)
- Loestrin 1/20 (21)
- Loestrin Fe 1.5/30 (28)
- Loestrin Fe 1/20 (28)
- Lomedia 24 Fe
- Loryna (28)
- Loseasonique
- Low-ogestrel (28)
- Lutera (28)
- Marlissa
- Menest
- Menostar
- Microgestin 1.5/30 (21)
- Microgestin 1/20 (21)
- Microgestin Fe 1.5/30 (28)
- Microgestin Fe 1/20 (28)
- Mimvey
- Minastrin 24 Fe
- Minivelle
- Mircette (28)
- Modicon (28)
- Mono-linyah
- Mononessa (28)
- Myzilra
- Natazia
- Necon 0.5/35 (28)
- Necon 1/35 (28)
- Necon 1/50 (28)
- Necon 10/11 (28)
- Necon 7/7/7 (28)
- norelgestrom-ethinyl estradiol
- noreth-ethinyl estradiol-iron
- norethin-e.estradiol triphasic
- norethin-eth estrad biphasic
- norethindrone ac-eth estradiol
- norethindrone-e.estradiol-iron
- norethindrone-ethin estradiol
- norethindrone-mestranol
- norgestimate-ethinyl estradiol
- norgestrel-ethinyl estradiol
- Norinyl 1+35 (28)
- Norinyl 1+50 (28)
- Nortrel 0.5/35 (28)
- Nortrel 1/35 (21)
- Nortrel 1/35 (28)
- Nortrel 7/7/7 (28)
- Nuvaring
- Ocella
- Ogen 2.5
- Ogestrel (28)
- Orsythia
- Ortho Evra
- Ortho Tri-cyclen (28)
- Ortho Tri-cyclen Lo (28)
- Ortho-cept (28)
- Ortho-cyclen (28)
- Ortho-novum 1/35 (28)
- Ortho-novum 7/7/7 (28)
- Ovcon-35 (28)
- Philith
- Pimtrea (28)
- Pirmella
- Portia
- Prefest
- Premarin
- Previfem
- Quartette
- Quasense
- Reclipsen (28)
- Safyral
- Seasonique
- Sprintec (28)
- Sronyx
- Syeda
- synthetic conj estrogens A
- synthetic conj estrogens B
- Tilia Fe
- Tri-estarylla
- Tri-legest Fe
- Tri-linyah
- Tri-norinyl (28)
- Tri-previfem (28)
- Tri-sprintec (28)
- Trinessa (28)
- Trivora (28)
- Vagifem
- Velivet Triphasic Regimen (28)
- Vestura (28)
- Viorele (28)
- Vivelle-dot
- Vyfemla (28)
- Wera (28)
- Wymzya Fe
- Yasmin (28)
- Yaz 28
- Zarah
- Zenchent (28)
- Zenchent Fe
- Zeosa
- Zovia 1/35E (28)
- Zovia 1/50E (28)
- Hyperprolinemia
Contraindicated
- Meningitis
- Thromboembolic disorder
Severe
Moderate
- Hemolysis
- Kidney disease with reduction in GFR
- Predisposition to thrombosis
- Transfusion related acute lung injury
HIZENTRA (IMMUNE GLOBULIN,GAMMA(IGG))
- Primary immune deficiency disorder
- Agammaglobulinemia
- Chronic inflammatory demyelinating polyneuropathy
- Common variable agammaglobulinemia
- Severe combined immunodeficiency disease
- Wiskott-aldrich syndrome
- X-linked agammaglobulinemia
- Fever
- Injection site sequelae
- Skin rash
- Sore throat
- Fatigue
- Headache disorder
- Nausea
More Frequent
Severe
Less Severe
- Pain
- Back pain
- Cough
- Diarrhea
- Migraine
- Upper abdominal pain
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Hemolysis
- Hypersensitivity drug reaction
- Kidney disease with reduction in GFR
- Non-infective meningitis
- Thromboembolic disorder
- Thrombotic disorder
Less Severe
- Induration of skin
- Pruritus of skin
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Immune Globulin (Subcutaneous)
No safety and efficacy studies age < 2 years.
- 1 Day – 2 Years
- No safety and efficacy studies age < 2 years.
Immune Globulin,gamma (igg)
- Severity Level:
2
- Additional Notes: Insuff human/animal data avail, consider maternal tx benefit vs poss fetal risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Immune Globulin,gamma (igg)
Insufficient data available.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available. |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Immune Globulin Parenteral (human)
General-Administer at the minimum infusion rate and do not exceed recommended dose. Renal-Increased risk of acute kidney injury in patients with decreased renal function. Cardiovascular-May be at increased risk of thrombosis. Assure adequate hydration and not volume depleted. Risk increases with immobility, hyperviscosity and underlying cardiovascular risks.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- This medication may rarely cause serious blood clots (such as pulmonary embolism, stroke, heart attack, deep vein thrombosis). You may be at increased risk for blood clots if you are an older adult, are severely dehydrated, have a catheter in a vein close to your heart for administering medications, or have a history of blood clots, heart/blood vessel disease, heart failure, stroke, or if you are immobile (such as very long plane flights or bedridden). If you use estrogen-containing products, these may also increase your risk.
Before using this medication, discuss the risks and benefits and if you have any of these conditions, report them to your doctor or pharmacist. The risk of blood clots may be decreased by infusing this medication more slowly or by using a less concentrated form of this medication if available. Being adequately hydrated before receiving this medication may also help reduce this risk. Get medical help right away if any of these side effects occur: shortness of breath/rapid breathing, chest/jaw/left arm pain, unusual sweating, sudden dizziness/fainting, pain/swelling/warmth in the arm/leg, sudden/severe headache, slurred speech, weakness on one side of the body, sudden vision changes, or confusion.
| Agammaglobulinemia | |
| D80.0 | Hereditary hypogammaglobulinemia |
| D80.1 | Nonfamilial hypogammaglobulinemia |
| Chronic inflammatory demyelinating polyneuropathy | |
| G61.81 | Chronic inflammatory demyelinating polyneuritis |
| Common variable agammaglobulinemia | |
| D80.1 | Nonfamilial hypogammaglobulinemia |
| D83 | Common variable immunodeficiency |
| D83.0 | Common variable immunodeficiency with predominant abnormalities of b-cell numbers and function |
| D83.1 | Common variable immunodeficiency with predominant immunoregulatory t-cell disorders |
| D83.2 | Common variable immunodeficiency with autoantibodies to b- or t-cells |
| D83.8 | Other common variable immunodeficiencies |
| D83.9 | Common variable immunodeficiency, unspecified |
| Primary immune deficiency disorder | |
| D84.9 | Immunodeficiency, unspecified |
| Severe combined immunodeficiency disease | |
| D81.0 | Severe combined immunodeficiency [SCId] with reticular dysgenesis |
| D81.1 | Severe combined immunodeficiency [SCId] with low t- and b-cell numbers |
| D81.2 | Severe combined immunodeficiency [SCId] with low or normal b-cell numbers |
| D81.31 | Severe combined immunodeficiency due to adenosine deaminase deficiency |
| Wiskott-aldrich syndrome | |
| D82.0 | Wiskott-aldrich syndrome |
| X-linked agammaglobulinemia | |
| D80.0 | Hereditary hypogammaglobulinemia |
| 0-9 | A-Z |
|---|---|
| D80.0 | Hereditary hypogammaglobulinemia |
| D80.0 | Hereditary hypogammaglobulinemia |
| D80.1 | Nonfamilial hypogammaglobulinemia |
| D80.1 | Nonfamilial hypogammaglobulinemia |
| D81.0 | Severe combined immunodeficiency [SCId] with reticular dysgenesis |
| D81.1 | Severe combined immunodeficiency [SCId] with low t- and b-cell numbers |
| D81.2 | Severe combined immunodeficiency [SCId] with low or normal b-cell numbers |
| D81.31 | Severe combined immunodeficiency due to adenosine deaminase deficiency |
| D82.0 | Wiskott-aldrich syndrome |
| D83 | Common variable immunodeficiency |
| D83.0 | Common variable immunodeficiency with predominant abnormalities of b-cell numbers and function |
| D83.1 | Common variable immunodeficiency with predominant immunoregulatory t-cell disorders |
| D83.2 | Common variable immunodeficiency with autoantibodies to b- or t-cells |
| D83.8 | Other common variable immunodeficiencies |
| D83.9 | Common variable immunodeficiency, unspecified |
| D84.9 | Immunodeficiency, unspecified |
| G61.81 | Chronic inflammatory demyelinating polyneuritis |
Formulary Reference Tool